Clinical trial
Pixantrone (BBR 2778) Versus Other Chemotherapeutic Agents for Third-line Single Agent Treatment of Patients With Relapsed Aggressive Non-Hodgkin's Lymphoma: A Randomized, Controlled, Phase III Comparative Trial
NCT00088530 is registered in ClinicalTrials.gov with CTI BioPharma as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Pixantrone (BBR 2778) Versus Other Chemotherapeutic Agents for Third-line Single Agent Treatment of Patients With Relapsed Aggressive Non-Hodgkin's Lymphoma: A Randomized, Controlled, Phase III Comparative Trial
- Lead sponsor
- CTI BioPharma
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- July 31, 2004
- Completion date
- July 31, 2010
- Enrollment
- 140 (actual)
- Sites
- 99
Conditions
As the registry lists them; a condition with its own page is linked.